var data={"title":"Vedolizumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vedolizumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/736470?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vedolizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vedolizumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24932520\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Entyvio</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502964\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Entyvio</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24891660\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gastrointestinal Agent, Miscellaneous;</li>\n      <li>\n        Monoclonal Antibody;</li>\n      <li>\n        Monoclonal Antibody, Selective Adhesion-Molecule Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066769\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Prior to initiating treatment, all patients should be brought up to date with all immunizations according to current immunization guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease or ulcerative colitis:</b> IV: 300 mg at 0, 2, and 6 weeks and then every 8 weeks thereafter.  Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066770\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066771\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066772\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Discontinue use with jaundice or signs/symptoms of hepatic injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24932521\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Entyvio: 300 mg (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24932519\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25119218\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Entyvio: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM491477.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giqgzdC5qtT9Vs/YoN9QxQfw==&amp;TOPIC_ID=95501\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM491477.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066773\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 30 minutes.  Do not administer by IV push or bolus. Following infusion , flush with 30 mL of sterile 0.9% sodium chloride injection.  Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; discontinue if a reaction occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24891643\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease:</b> Treatment of moderately to severely active Crohn disease in patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis</b> Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response with, were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25119219\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (4% to 13%; neutralizing: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (3%), skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&ge;3 x ULN: &lt;2%), increased serum AST (&ge;3 x ULN: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (4%), limb pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (7%), cough (5%), bronchitis (4%), oropharyngeal pain (3%), sinusitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (9%), infusion related reaction (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%: Anaphylaxis, hepatitis, hypersensitivity reaction, increased serum bilirubin, increased serum transaminases, infection (including anal abscess, sepsis, tuberculosis, salmonella sepsis, listeria meningitis, giardiasis, cytomegaloviral colitis), malignant neoplasm (excluding dysplasia and basal cell carcinoma)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24891662\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious or severe hypersensitivity to vedolizumab or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Patients with active severe infections or opportunistic infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066758\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions:  Hypersensitivity reactions have been reported including anaphylaxis.   Allergic reactions including dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have also been observed. Symptom onset may vary from during the infusion, immediately post-infusion, to several hours post-infusion. If serious reactions occur, discontinue administration immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infections: Use may be associated with an increased risk for developing infections; most commonly reported infections included upper respiratory and nasal mucosa. Serious infections have also been reported in patients treated, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, <i>Listeria</i> meningitis, giardiasis, and cytomegaloviral colitis. Therapy is not recommended in patients with uncontrolled, active, severe infections.  If a patient develops a serious infection, consider discontinuing therapy. Use with caution in patients with a history of recurring severe infections.  Screening for tuberculosis should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Liver injury: Elevations of transaminase and/or bilirubin have been reported in patients receiving vedolizumab.  Discontinue therapy in patients with jaundice or other evidence of significant liver injury such as fatigue, anorexia, right upper abdominal discomfort, or dark urine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Progressive multifocal leukoencephalopathy: Integrin receptor antagonists have been associated with progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system caused by the John Cunningham (JC) virus. Monitor patients for any new onset or worsening of neurological signs and symptoms including progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Symptoms may progress over days to weeks and can lead to death or severe disability in weeks to months. If PML is suspected withhold therapy and refer to a neurologist; if confirmed, discontinue therapy permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immunizations: Patients should be brought up to date with all immunizations according to immunization guidelines before initiating therapy. Live vaccines should not be given concurrently unless the benefits outweigh the risks; there are no data on the secondary transmission of infection by live vaccines with vedolizumab. Non-live vaccines may be given concurrently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24958204\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24958201\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95501&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Vedolizumab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Vedolizumab may enhance the adverse/toxic effect of Natalizumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Travelers' Diarrhea and Cholera Vaccine: Vedolizumab may diminish the therapeutic effect of Travelers' Diarrhea and Cholera Vaccine.  Management: Administer travelers' diarrhea andl cholera vaccine prior to initiation of therapy with vedolizumab.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066754\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066755\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester. Any adverse pregnancy effect would likely be greater during the second and third trimesters of pregnancy.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to vedolizumab during pregnancy in a pregnancy exposure registry. Information about the registry can be obtained by calling 1-877-825-3327.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066757\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if vedolizumab is excreted in breast milk. The manufacturer recommends that caution be exercised when administering vedolizumab to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066775\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; LFTs; tuberculosis screening according to local practice; signs/symptoms of infection; any new onset or worsening of neurological signs and symptoms </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066763\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vedolizumab is a humanized monoclonal antibody that binds to the alpha4beta7 integrin and blocks the interaction of alpha4beta7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. The interaction of the alpha4beta7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25066765\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 5 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Half-life elimination: 25 days (serum, at 300 mg dosage)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25211461\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Entyvio Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $7,035.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25233230\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Entyvio (AT, AU, CZ, DE, DK, EE, FR, GB, HK, HR, HU, IE, IL, IS, LT, LU, MT, MY, NL, NO, PH, PL, PT, RO, SE, SG, SI, SK);</li>\n      <li>Kynteles (AU, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Entyvio (vedolizumab) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Entyvio (vedolizumab) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vedolizumab-drug-information/abstract-text/28780013/pubmed\" target=\"_blank\" id=\"28780013\">28780013</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95501 Version 59.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24932520\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46502964\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F24891660\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F25066769\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F25066770\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25066771\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25066772\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24932521\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F24932519\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25119218\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25066773\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24891643\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F25119219\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F24891662\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F25066758\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24958204\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24958201\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F25066754\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F25066755\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F25066757\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25066775\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F25066763\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F25066765\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F25211461\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25233230\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/95501|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vedolizumab-patient-drug-information\" class=\"drug drug_patient\">Vedolizumab: Patient drug information</a></li></ul></div></div>","javascript":null}